Crude and adjusted HRs of ischaemic and total stroke by statin use
| Statin use* | |||||
|---|---|---|---|---|---|
| Overall | Events | No (reference) | Yes | p Value | |
| n | n (%) | HR | HR (95% CI) | ||
| Ischaemic stroke | |||||
| Model 1† | 60 353 | 1643 (2.7) | 1.00 | 0.997 (0.89 to 1.12) | 0.964 |
| Model 2‡ | 58 135 | 1569 (2.7) | 1.00 | 0.86 (0.74 to 0.98) | 0.029 |
| Effect modification§ | |||||
| Antiplatelet agents¶ | 0.272 | ||||
| No | 47 029 | 1144 (2.4) | 1.00 | 0.89 (0.76 to 1.05) | |
| Yes | 11 106 | 425 (3.8) | 1.00 | 0.78 (0.62 to 0.97) | |
| Total stroke | |||||
| Model 1† | 60 353 | 2302 (3.8) | 1.00 | 0.99 (0.90 to 1.10) | 0.887 |
| Model 2‡ | 58 135 | 2201 (3.8) | 1.00 | 0.86 (0.77 to 0.97) | 0.016 |
| Effect modification§ | |||||
| Antiplatelet use¶ | 0.314 | ||||
| No | 47 029 | 1623 (3.5) | 1.00 | 0.85 (0.74 to 0.97) | |
| Yes | 11 106 | 578 (5.2) | 1.00 | 0.89 (0.74 to 1.08) | |
See text for definitions of each study variable.
*Statin use is modelled as time varying covariate. That is, USE(t)=0 when patient is not taking statin and USE(t)=1 once patient begins taking statin.
†Model 1 adjusted for age, income, marital status, enrolment status in the HT, DM and extension study, baseline history of cerebrovascular disease, hypertension, use of antiplatelet agents and anticoagulants.
‡Model 2 adjusted for variables in model 1 plus BMI, waist-to-hip ratio, physical activity, smoking status, baseline history of diabetes, baseline history of high cholesterol requiring pharmacological treatment and baseline history of cardiac disease.
§Adjusted for same variables as model 2 and include interactions terms, statin use and antiplatelet use interaction for ischaemic stroke.
¶Antiplatelet agents included aspirin, dipyridamole and ticlopidine.
BMI, body mass index; DM, dietary modification; HT, hormone therapy.